Concomitant Alpha-Interferon and Chemotherapy in Advanced Squamous Cell Carcinoma of the Head and Neck

Benasso, Marco; Merlano, Marco; Blengio, F.; Cavallari, Monica; Rosso, Riccardo; Toma, Salvatore

doi:10.1097/00000421-199312000-00001

Cited by 17 publications

(4 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These favorable results suggested the usefulness of this kind of combined therapy and have attracted widespread attention. Subsequently, similar trials have also been undertaken for various solid tumors of the digestive tract and other organs with CDDP and 5-FU, the most frequently used anticancer agents [22][23][24][25][26][27].…”

Section: Discussionmentioning

confidence: 99%

“…As the optimal schedule of IFN administration for obtaining the most synergistic effects of anticancer drugs and interferon has not been clarified, this treatment schedule had been designed in the same way as the minimal dose of reported regimens [24,28] and as the treatment schedule for type C chronic hepatitis in which the method is established and the incidence of side effects clear.…”

Section: Discussionmentioning

confidence: 99%

“…Cisplatin (CDDP) has not only a favorable effect on HCC [14,15], it also synergistically modulates the effect of 5-FU [16,17]. Furthermore, it has been reported that interferonalpha (IFN·) augments the cytotoxicity of 5-FU and CDDP based on clinical and basic data for colorectal cancers [18][19][20][21] and other solid malignancies [22][23][24][25][26][27]. Preliminary data of advanced HCC [28] and preclinical data from studies of a human HCC cell line [29] have suggested that the cytotoxic effects of CDDP and 5-FU are enhanced by IFN·.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Clinical Pilot Study of Intrahepatic Arterial Chemotherapy with Methotrexate, 5-Fluorouracil, Cisplatin and Subcutaneous Interferon-Alpha-2b for Patients with Locally Advanced Hepatocellular Carcinoma

et al. 1997

View full text Add to dashboard Cite

To evaluate the efficacy of methotrexate (MTX)-5-fluorouracil (5-FU), cisplatin (CDDP), and interferon-α-2b(IFNα-2b) combination therapy, we conducted a clinical pilot study in patients with locally advanced hepatocellular carcinoma (HCC). Sixteen patients, who had received no prior treatment for the HCC, with portal tumor thrombosis in the main trunk or in the major branch were enrolled in the study. IFNα-2b (3 × 10⁶ units) was injected subcutaneously 3 times per week. After a bolus administration of MTX (30 mg/m²), CDDP (75 mg/m²) and thereafter 5-FU (750 mg/m²) were given weekly by intrahepatic arterial infusion. In 15 eligible patients, there were 1 complete response (CR) and 6 partial responses (PR) with a response rate of 46.7%. Median survival of the 15 patients was 7 months, and the 2-year survival rate of CR and PR patients was 57.1%. There was severe transient hematologic toxicity. More than grade 2 nausea/vomiting was noted in >50%. In conclusion, the IFNα-2b combination chemotherapy demonstrated good response in patients with locally advanced HCC. This treatment should be tried in a controlled study.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Clinical Pilot Study of Intrahepatic Arterial Chemotherapy with Methotrexate, 5-Fluorouracil, Cisplatin and Subcutaneous Interferon-Alpha-2b for Patients with Locally Advanced Hepatocellular Carcinoma

et al. 1997

View full text Add to dashboard Cite

show abstract

“…Cisplatin (CDDP) does not only have a favorable effect on HCC [11,12], but it also synergistically modulates the effect of 5-FU [13,14]. Furthermore, it has been reported that interferon-␣ (IFN-␣) augments the cytotoxicity of 5-FU and CDDP in colorectal cancers [15][16][17][18] and other solid malignancies [19][20][21][22][23][24] in clinical and experimental settings. Preliminary results with advanced HCC [25], including our own [26], have suggested that cytotoxic effects of CDDP and 5-FU are enhanced by IFN-␣.…”

mentioning

confidence: 99%

Combination Chemotherapy for Advanced Hepatocellular Carcinoma Complicated by Major Portal Vein Thrombosis

2002

View full text Add to dashboard Cite

Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck. A southwest oncology group study

Hussain

Benedetti

Smith³

et al. 1995

Cancer

View full text Add to dashboard Cite

Background. Recurrent cancer of the head and neck after primary therapy is almost always fatal. The combination of 5‐fluorouracil (5‐FU) and cisplatin is considered the best available therapy but complete response rates remain too low to affect survival. This study was designed to evaluate the complete response rate and toxicity of 5‐FU, cisplatin, and alpha‐interferon (α‐IFN) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Methods. Fifty eligible patients with recurrent or metastatic SCCHN and no prior chemotherapy (40 men, 10 women; age range, 26–77 years; median, 59 years; 82% white; 88% had prior surgery and 92% had prior radiation therapy) were treated every 21 days with 96‐bour infusion of 5‐FU 1000 mg/m2/day; cisplatin 100 mg/m2, day 1; and α‐IFN 5 × 106 units/day, days 1–4. Results. One hundred fifty‐seven courses of chemotherapy were administered, with a median of three courses. Thirty‐seven patients experienced Grade 3 or 4 toxicity. Of the 17 patients with Grade 4 toxicity; 12 had hematologic toxicity, 3 stomatitis, and 2 vomiting. Two additional patients died of myelosuppression‐related sepsis. Of the 50 patients, 3 (6%) achieved a complete response, five (10%) had a partial response, 3 (6%) had unconfirmed response (1 complete and 2 partial), 10 (20%) had stable disease, 17 (34%) progressed, and 12 (24%) were considered nonresponders owing to early death (6) or inadequate assessment (6). The median survival was 5 months. Conclusion. The complete response rate of patients with recurrent or metastatic SCCHN treated with 5‐FU, cisplatin, and α‐IFN does not appear to be superior to that observed for 5‐FU and cisplatin. Alpha‐interferon appears to augment hematologic and gastrointestinal toxicities associated with this combination.

show abstract

Concomitant Alpha-Interferon and Chemotherapy in Advanced Squamous Cell Carcinoma of the Head and Neck

Cited by 17 publications

References 6 publications

Clinical Pilot Study of Intrahepatic Arterial Chemotherapy with Methotrexate, 5-Fluorouracil, Cisplatin and Subcutaneous Interferon-Alpha-2b for Patients with Locally Advanced Hepatocellular Carcinoma

Clinical Pilot Study of Intrahepatic Arterial Chemotherapy with Methotrexate, 5-Fluorouracil, Cisplatin and Subcutaneous Interferon-Alpha-2b for Patients with Locally Advanced Hepatocellular Carcinoma

Combination Chemotherapy for Advanced Hepatocellular Carcinoma Complicated by Major Portal Vein Thrombosis

Evaluation of 96-hour infusion fluorouracil plus cisplatin in combination with alpha interferon for patients with advanced squamous cell carcinoma of the head and neck. A southwest oncology group study

Contact Info

Product

Resources

About